Free Trial
→ What is “gold skimming”? (From Brownstone Research) (Ad)tc pixel
NASDAQ:IMRX

Immuneering Q2 2025 Earnings Report

Immuneering logo
$5.38 +0.20 (+3.86%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$5.35 -0.03 (-0.56%)
As of 04:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immuneering EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.40
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Announcement Details

Quarter
Q2 2025
Date
8/13/2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Immuneering's Q1 2026 earnings is estimated for Thursday, May 14, 2026, based on past reporting schedules, with a conference call scheduled on Monday, May 18, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immuneering's Q2 2025 Press ReleasePress Release
(8-K)
Immuneering's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Immuneering Earnings Headlines

Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Moderate Buy" by Brokerages
May 12 at 2:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30772724
We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
May 6, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/were-hopeful-immuneering-nasdaq-imrx-145323224.html
Is this AI lab Elon’s SpaceX lifeline?
Elon Musk went from calling one AI lab 'evil' to striking a deal giving it access to SpaceX's entire Colossus 1 supercomputer - all in three months. The lab saw 80x revenue and usage growth in Q1 2026 alone, when it had only planned for 10x. 60-year Wall Street veteran Marc Chaikin calls it the most important potential IPO of 2026 - and says he's found a pre-IPO backdoor trading under $40 per share. His stock-rating system previously turned bullish on Nvidia in 2014 before a nearly 50,000% run, and on Vertiv before a 3,985% surge.tc pixel
 |  Chaikin Analytics (Ad)
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)
April 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MCK/pressreleases/1445806/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-and-mckesson-mck/
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG) and Immuneering (IMRX)
April 21, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1427322/analysts-offer-insights-on-healthcare-companies-passage-bio-pasg-and-immuneering-imrx/
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
April 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/21/3278411/0/en/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting.html
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

View Immuneering Profile
Earnings Tools